Roche-AC Immune's Crenezumab Fails To Show Benefit In Sub-Set Of Alzheimer's Patients

  • Roche Holdings AG RHHBY said its Alzheimer's medicine crenezumab did not slow or prevent cognitive decline in people with a specific genetic mutation that causes early-onset disease.
  • Crenezumab did not show a statistically significant clinical benefit in its co-primary endpoints assessing the rate of change in cognitive abilities or episodic memory function.
  • The Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial evaluated the potential of crenezumab in 252 people.
  • Minor numerical differences favoring crenezumab were observed across the co-primary and multiple secondary and exploratory endpoints, but these were not statistically significant. 
  • No new safety issues were identified. Further analyses of data are ongoing. 
  • Initial data will be presented at the Alzheimer's Association International Conference in August.
  • Within its Alzheimer's pipeline, Roche is also evaluating gantenerumab in autosomal dominant Alzheimer's disease, as well as for preventing sporadic Alzheimer's and treating early Alzheimer's in late-stage trials. 
  • The phase 3 GRADUATE studies results of gantenerumab in early Alzheimer's are expected in Q4, 2022.
  • Crenezumab is an investigational treatment discovered by AC Immune SA ACIU and designed to neutralize a pathological species of the beta-amyloid protein called oligomers. 
  • It was developed by Genentech, a member of the Roche Group, under a license and collaboration agreement established in 2006.
  • Price Action: ACIU shares are down 27.62% at $2.07 during the premarket session on the last check Thursday. RHHBY shares closed at $38.53 on Wednesday.

Posted In: Briefswhy it's movingBiotechLarge CapNewsPenny StocksHealth CareMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.